- Home
- CCM vs BOLD Comparison
CCM vs BOLD Comparison
Compare CCM & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- BOLD
- Stock Information
- Founded
- CCM 1997
- BOLD 2018
- Country
- CCM China
- BOLD United States
- Employees
- CCM N/A
- BOLD N/A
- Industry
- CCM Medical/Nursing Services
- BOLD
- Sector
- CCM Health Care
- BOLD
- Exchange
- CCM Nasdaq
- BOLD Nasdaq
- Market Cap
- CCM 33.3M
- BOLD 30.3M
- IPO Year
- CCM 2009
- BOLD 2024
- Fundamental
- Price
- CCM $5.66
- BOLD $1.10
- Analyst Decision
- CCM
- BOLD Buy
- Analyst Count
- CCM 0
- BOLD 3
- Target Price
- CCM N/A
- BOLD $4.00
- AVG Volume (30 Days)
- CCM 2.5K
- BOLD 362.2K
- Earning Date
- CCM 04-25-2025
- BOLD 08-11-2025
- Dividend Yield
- CCM N/A
- BOLD N/A
- EPS Growth
- CCM N/A
- BOLD N/A
- EPS
- CCM N/A
- BOLD N/A
- Revenue
- CCM $52,603,198.00
- BOLD N/A
- Revenue This Year
- CCM N/A
- BOLD N/A
- Revenue Next Year
- CCM N/A
- BOLD N/A
- P/E Ratio
- CCM N/A
- BOLD N/A
- Revenue Growth
- CCM N/A
- BOLD N/A
- 52 Week Low
- CCM $3.80
- BOLD $1.00
- 52 Week High
- CCM $10.90
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- CCM 40.37
- BOLD N/A
- Support Level
- CCM $5.57
- BOLD N/A
- Resistance Level
- CCM $5.95
- BOLD N/A
- Average True Range (ATR)
- CCM 0.23
- BOLD 0.00
- MACD
- CCM 0.00
- BOLD 0.00
- Stochastic Oscillator
- CCM 48.19
- BOLD 0.00
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.